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RT-PCRs to detect SARS-CoV-2 RNA is key to manage the COVID-19 pandemic. We analyzed SARS-CoV-2
viral loads from 220323 RT-PCR results according to samples types, gender, age, and health units. Viral
load did not show any difference across age and appears to be a poor predictor of disease outcome. SARS-
CoV-2 viral load showed similar high viral loads than the one observed for RSV and influenza B. The
importance of viral load to predict contagiousness and to assess disease progression is discussed.
© 2020 Published by Elsevier Masson SAS on behalf of Institut Pasteur.At the beginning of January 2020, the cluster of SARS-CoV-2
cases identified in Wuhan City, Hubei Province (China) rapidly
spread to other regions in China and to other countries, causing a
world pandemic [1,2]. Quantitative reverse transcription polymer-
ase chain reaction (RT-PCR) represents a key diagnostic tool for
patients with suspected SARS-CoV-2 infection. Viral-specific genes,
such as the Envelope (E), the RdRP/Helicase (Hel), the spike protein
encoding gene (S), as well as Nucleocapsid (N) were used as mo-
lecular targets and combination of these genes have been recom-
mended by theWHO [3,4]. We introduced the E, RdRP, and N genes
RT-PCRs in our fully automated molecular diagnostic platform
(MDx platform) [5]. A lower sensitivity of the RT-PCRs targeting the
RdRP and N genes, compared to that targeting the E gene was
observed leading us to use solely the E gene, as RT-PCR target. Latter
during the pandemic, the cobas SARS-CoV-2 test (Roche, Basel,
Switzerland) became available targeting the ORF1/a, a non-
structural region for specific detection of SARS-CoV-2 and a
conserved region in the E gene, for pan-Sarbecovirus detection. The
pan-Sarbecovirus primers and probe can also detect the SARS-CoV-
1 virus, however not currently circulating [6].on behalf of Institut Pasteur.We determined the correlation between the cycle threshold (Ct)
value and viral load and investigated the distribution of viral loads
across sex, age, and healthcare departments and as well as against
other respiratory viruses. The report of RT-PCR SARS-CoV-2 viral
loads raised also several questions regarding the use of this infor-
mation for the laboratory as an internal quality assessment tool (i)
to predict contagiousness of patients and hence to guide epide-
miological decisions, especially for hospitalized patients and (ii) to
predict the patient prognosis and assess disease progression. These
important questions will be discussed here.
1. Material and methods
1.1. Data
Data from 19,832 SARS-CoV-2 RT-PCR results from patients with
suspected COVID-19 were collected from 1st February to 27th April
2020 at the diagnostic microbiology laboratory of the Lausanne’s
University Hospital (CHUV), representing 4172 positive cases.
1.2. SARS-CoV-2 RT-PCR, cycle thresholds and viral load
quantification
SARS-CoV-2 was detected in clinical specimenwith i) a in-house
RT-PCR targeting the E-gene introduced in our automated molec-
ular diagnostic platform (MDx platform) [5] and with the cobas
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Switzerland). The primers and probes for the E-gene PCR was those
described by Corman and colleague [4]. Cts of the MDx platform
targeting the E gene were converted to viral load using either a
plasmid containing the target sequence of the PCR obtained from
RD-Biotech (Besançon, France) or using purified viral RNA, kindly
provided by the Institute of Virology of the University of Berlin, la
Charite [4]. Both approaches showed similar virus quantifications
and the following equation derived from RNA quantification was
used: 0.27Ctþ13.04. A comparative analysis of the Cts values
obtained from our MDx platform compared to the cobas SARS-CoV-
2 test showed a good congruency for Cts related to the E gene. This
led us to use the E gene RT-PCR Cts values of both platforms in the
present analyses.1.3. Clinical specimens
Among the 22,323 specimens collected, only the initial sample
per patient was kept (19,832 samples with 4172 positives) and only
nasopharyngeal and/or nasal swabs (NPS) were used (19,728
samples). Viral loads in different specimen types were instigated
using multiple samples per patient as most of these investigations
were performed after the first positive test, usually an NPS. Com-
parison of viral load in different hospital units was also performed
using more than one sample per patient.1.4. Comparison of SARS-CoV-2 with other respiratory viruses
6050 RT-PCR of 14 other respiratory viruses were extracted from
our database over a period of 5 years (2015e2020): Influenza A and
B, Respiratory Syncytial Virus (RSV), adenovirus, parainfluenza 1e4,
Coronaviruses E229, OC43, HKU1, NL63, Pan-entero/rhinovirus and
HumanMetapneumovirus and Ct values were obtained on theMDx
platform and converted to viral loads, as previously reported [5].
For Influenza A and B and RSV the Xpert® Xpress Flu/RSV was used
and converted to viral load according to Zou et al. [7]. Only naso-
pharyngeal and nose swabs were included.1.5. Statistical analysis
Data were process with Rstudio and plotted using ggplot2.
Median is presented in all graphs. Statistical significance of viral
loads were assessed using a parametric paired t-test and the two-
tailed p-values interpretation are written on the graphs.Fig. 1. A: Histogram of SARS-CoV-2 viral loads. B: Time-course analyses of SARS-CoV-2 viral l
6182. Results
2.1. SARS-CoV-2 viral load across the pandemic and among other
respiratory viruses
We observed a broad distribution of viral load values (Fig. 1A)
with an evolution over the pandemic period that mirrored the
epidemiological observations of SARS-CoV-2 infection in
Switzerland [8] (Fig. 1B). The first cases occurred earlyMarch with a
peak of the COVID-19 epidemic mid-March followed by a 2 weeks
stationary phase before a slow decrease. Interestingly, the median
viral load was higher in the first phase of the outbreak as compared
to the following period. This is likely linked to the diagnostic of
newly infected symptomatic persons with high viral loads during
the first phase, compared to a more heterogeneous population
tested in the following months. The initial viral load of SARS-CoV-2
was compared to 14 other respiratory viruses (Fig. 2A) [9]. We
found that although significant differences in viral loads exist
across the different viruses and compared to SARS-CoV-2, SARS-
CoV-2 exhibits similar viral load than RSV and Influenza B and than
other coronaviruses. The range of viral load is overall similar be-
tween all the different respiratory viruses, with some subjects
exhibiting very high load while others may exhibit much lower
viral load, reflecting likely different sampling times during the
course of the disease.
2.2. SARS-Cov-2 viral loads stratified by gender and age
A higher number of tests was achieved in women than in men
(35% of difference); however the rate of positive results was similar
for both sex (Figs. S1AeB) and both genders showed comparable
viral load distribution (Fig. 2B). Stratification of positive samples by
age groups showed that older individuals, when tested, were likely
to be proportionally more frequently positive than the rest of the
population, while young children showed very low percentages of
positivity despite being rarely tested (Figs. S1CeD). Interestingly,
viral loads categorization based on 5-year brackets ages showed no
significant differences across age groups (Fig. 2C). Although limited
by the low samples size, the pediatric age groups showed viral load
values comparable to adults.
2.3. SARS-Cov-2 viral loads across different hospital units
We focused on the Intensive care unit (ICU), the internal med-
icine (IM) department, the emergency unit (EU) and patientsoads across time. Viral loads mirrored the reported COVID-19 infections in Switzerland.
Fig. 2. A: Viral loads of 14 respiratory viruses compared to SARS-CoV-2. HMPV: Human-metapneumovirus, HPIV1-4: Human Parainfluenza Viruses 1e4, InfA and B: Influenza
viruses A and B; RSV: Respiratory Syncytial Virus. m represents the median, n the number of observations, and the percentage of positive test is presented. Statistical significance of
viral loads of SARS-CoV-2 was assessed against the other viruses. BeC: Viral loads distribution of SARS-CoV-2 across sex and age showed comparable values among all groups. D:
Initial viral loads of SARS-CoV-2 in different hospital departments. ICU first and ICU max correspond to respectively the first or highest sample recorded for patients latter admitted
to the ICU. Statistical significance of viral loads was assessed against the SU samples (upper stars), and against the ICU (lower stars). E: Distribution of viral loads across different
specimens. Statistical significance of viral loads was assessed against the NPS samples AS: anal swab, BAL: bronchoalveolar lavage, CSF cerebrospinal fluid, NTS: nasal-throat swab,
TS: throat swab. P-values: ns: p > 0.05, *: p  0.05, **; p  0.01, ***; p  0.001, ****: p  0.0001.
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outbreak. This stratification per unit was used to investigate
possible differences in viral loads in patients with several days of
evolution since first symptoms and with a severe lung disease
(ICU), versus subjects sick enough to get hospitalized (IM) or
admitted to the EU, to patients screened with mild symptoms (SU).
To assess if the initial viral load could correlate with disease pro-
gression, we traced back, when available, the initial or the highest
viral load values obtained in other departments for all patient
hospitalized in ICU and showed that this value is not significantly
higher than the one obtain for all other patients (Fig. 2D). Inter-
estingly, patients latter hospitalized in ICU showed the lowest viral
load in the upper respiratory tract compared to all other patients
(Fig. 2D). This might reflect the evolution of COVID-19 infection,
from the upper respiratory tract where it causes mild symptoms
such as a fever and cough to a more severe form when the lower
respiratory tract are affected [10e12]. Furthermore, in the sec-
ondary phase of the disease, inflammation rather than viral repli-
cation appears to predominate (although this was not formerly
established in the present work). These observations might also be
biased by the timing of the 1st nasopharyngeal test that was
sometimes done very late, i.e. at time of admission at the ICU.
Finally, geriatric patients did not show different viral loads.
2.4. SARS-Cov-2 viral loads across different specimens
Over the time course of the epidemic several, non-nasal speci-
mens were analysed mainly lower respiratory samples for patient
in the ICU (Figs. S1EeF). Although, lower viral load values were
obtained compared to the upper respiratory part (Fig. 2E), the
lower respiratory tract samples were often useful to allow an early
microbial diagnostic of COVID-19, and might prove to be useful to
assess the clinical prognosis and disease progression. Only few
blood samples were tested and only one of them was positive; this
suggest a low rate of viremia. Interestingly, SARS-CoV-2 was not
detected in urines. This was expected since respiratory tract vi-
ruses, which are not associated with a sustained viremia, are un-
likely to be shed in urines. Moreover, the absence of virus in the CSF
tested samples suggests that the serology should be considered as
first line test for meningoencephalitis and Guillain-Barre syn-
drome. Only a handful number of samples were positive for stools
and rectal swabs, due to limited number of subjects tested. Statis-
tical comparison across the different specimens was however
limited by the low number of data.
3. Discussion
Initial SARS-CoV-2 viral load is widely distributed ranging from
3 to 10 log copies/ml and the evolution of the viral load over-time
mirrored the evolution of SARS-CoV-2 infections in Switzerland.
The median viral load for SARS-CoV-2 in NPS was 6.78 log10 copies
per ml. This supports the fact that RT-PCR, which can detect less
than 100 copies per ml of samples, is a sensitive method for the
diagnostic of COVID-19. This is however limited by the quality of
specimen sampling and the time course of infection.
We also compared SARS-CoV-2 viral loads to that of other res-
piratory viruses in order to determine whether higher viral loads,
that could affect contagiousness, are observed. Although significant
differences were observed when compared to some other respira-
tory viruses, SARS-CoV-2 appears to exhibit similar viral load than
RSV and influenza B, as previously reported [9]. For respiratory
viruses other than Influenza and RSV, we have a bias towards
immunocompromised or severely ill patients, which might tend to
have higher viral loads. Interestingly, others reported that the
pattern of patients infected with SARS-CoV-2 resembles more to620patients infected with influenza [13] than SARS-CoV-1 [14]; the
former being characterized by increased infectiousness at time or
even before symptoms onset [15]. SARS-CoV-2 viral load appears to
be a poor predictor of disease outcome. Indeed neither the initial
nor the highest viral load of patients latter admitted to the ICU was
significantly higher than the specimens from patient treated in a
SU. This absence of correlation with the clinical outcome is also
supported (i) by other published data showing high viral load in
asymptomatic patients [15e18] and (ii) by the fact that asymp-
tomatic or minimally symptomatic patients can transmit the virus
[19]. We also observed that viral load seems not to correlate with
age. In particular, older individual and young children showed
similar viral loads than the general population [20e22]. Concen-
tration of the virus in the respiratory tract can indirectly reflects
contagiousness; however, viral load is not the only factor at play in
term of contagiousness, since nasal discharge and cough are clearly
important co-variables impacting transmission [23].
The clinical relevance and usefulness of viral load measures
appears to bemainly restricted to specifically classifying the patient
as being in the first phase of the disease with high viral load or
rather in the 2nd phase of the disease when viral load tends to
decrease and when inflammation predominates [12]. This may be
useful to help treatment decision, i.e. to use for instance anti-IL6 or
steroids in presence a cytokine storm or during a macrophage
activation syndrome. Indeed, COVID-19 disease severity is not
directly linked to viral replication in the upper and lower respira-
tory tracts but is also due to an unregulated inflammatory process
induced by the host immune response [12]. Interpretation of a
unique viral load value in a given patients should be done
cautiously since (i) there is a trend to a natural gradual decrease of
the viral load in the nasopharyngeal samples over time during the
course of the infection [15,16] and (ii) the absolute value of the viral
load in the nasopharyngeal samples may be highly different ac-
cording to the quality of sampling. Our laboratory decided to pro-
vide quantitative results to clinicians, now used not only for patient
care, but also to assess contagiousness, i.e. values below 1000
copies/ml may be considered at low risk of transmission. Of course,
decisions about patients isolation inside the hospital is not only
based on viral load but also takes into account (i) epidemiological
aspects such as the possible exposure of other immunocompro-
mised subjects and (ii) clinical presentation, since a patient with
cough and/or nasal discharge will be more contagious.
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